▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #1696 by analyst upside · 2026-06-27
ANAB
AnaptysBio, Inc.
Healthcare · Market Cap $2B · P/E 0x
ANALYST PRICE TARGET
+37.9%
implied upside to consensus target
Current Price $63.15
Consensus Target $87.09
Bull Target $140.0
Bear Target $70.0
Analysts Covering 11
ANALYST CONSENSUS - BUY
Strong Buy
3
Buy
8
Hold
1
Sell
0
52-Week Low $11.4
52-Week High $72.36
YTD Return +110.7%
FUNDAMENTALS
Market Cap $2B
P/E Ratio (TTM) N/A
Forward P/E 12.1x
EPS (TTM) $-1.02
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $232M
Profit Margin -11.5%
52-WEEK RANGE
52-Week Low $11.4
52-Week High $72.36
Current Price $63.15
Bear Target $70.0
Bull Target $140.0
● Now $63.15 ● Target $87.09
TRADING DATA
Avg Volume 714K
YTD Return +110.7%
Analyst Count 11
Consensus Buy
Upside to Target +37.9%
Last Updated 2026-06-27

ANALYST SUMMARY

AnaptysBio, Inc. (ANAB) is currently trading at $63.15 with a Wall Street consensus price target of $87.09, implying potential upside of 37.9% over the next 12 months. 11 analysts currently cover ANAB, with a consensus rating of Buy - 92% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $140.0, while the most cautious has a target of $70.0.

ANAB operates in the Healthcare sector with a market capitalisation of $2B. The stock is up 110.7% year-to-date and is currently trading near the upper end of its 52-week range of $11.4 – $72.36.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

ADUS +36.9%
Addus HomeCare Corporation
$2B · P/E 17.9x · Buy
INVA +50.6%
Innoviva, Inc.
$2B · P/E 3.8x · Buy
ANIP +33.4%
ANI Pharmaceuticals, Inc.
$2B · P/E 21.3x · Buy
HRMY +25.1%
Harmony Biosciences Holdings, Inc.
$2B · P/E 14.3x · Buy
AVAH +16.1%
Aveanna Healthcare Holdings Inc.
$2B · P/E 7.2x · Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for ANAB, with each firm's 90-day track record across all stocks we track. See full firm rankings →

UBS — Reiterated
Buy → Buy 2026-05-13 33% win rate (6 calls)
Barclays — Reiterated
Overweight → Overweight 2026-05-13 Building track record
Piper Sandler — Reiterated
Overweight → Overweight 2026-05-04 14% win rate (7 calls)
Leerink Partners — Reiterated
Outperform → Outperform 2026-04-28 29% win rate (7 calls)
Barclays — Reiterated
Overweight → Overweight 2026-04-22 Building track record
UBS — Reiterated
Buy → Buy 2026-04-21 33% win rate (6 calls)
Piper Sandler — Reiterated
Overweight → Overweight 2026-03-31 14% win rate (7 calls)
HC Wainwright & Co. reit
Buy → Buy 2026-03-30 31% win rate (48 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
49
out of 100
Coverage depth
19/30
Consensus clarity
8/30
Vote unanimity
20/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →